CONTINUING EDUCATION :: C DIFFICILE
• Testing strategies that minimize overdiagnosis of CDI will result in appropriate treatment for the patient. Treating car- riers can lead to patient harm and has been associated with an increased prevalence of antibiotic resistance, including VRE.12
Minimizing overdiagnosis represents good antibiotic
stewardship and helps to prevent the evolution of antibiotic- resistant strains.
REFERENCES
1. Guh AY,Mu Y,Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;(14) 382:1320–30. doi: 10.1056/NEJMoa1910215.
2. Lyerly DM, Boone JH, Carman RJ, et al. Clostridioides difficile the challenge, tests, and guidelines. ACS Infect. Dis. 2020;6(11):2818-2829. doi: org/10.1021/acsinfecdis.0c00290.
3. Kelly C, Fischer M, Allegretti J, et al. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021; 116(6):1124-1147.: doi: 10.14309/ajg.0000000000001278.
4. Kraft C, Mehta N. Is the ultrasensitive toxin immunoassay the solution to the goldilocks problem of Clostridioides difficile diagnostics? Oxford University Press, Infectious Diseases Society of America. Clin Infect Dis. 2021 Sep 19;ciab833. doi: 10.1093/cid/ciab833 .
5. Guti´errez RL, Riddle MS, Porter CK. Increased risk of functional gastrointes- tinal sequelae after Clostridium difficile infection among active duty United States military personnel (1998–2010). Gastroenter- ology. 2015;149(6):1408–14. doi: org/10.1053/j. gastro.2015.07.059.
6. Wadhwa A, Al Nahhas MF, Dierkhising RA, et al. High risk of postinfectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Ther. 2016;44(6):576–82. doi: 10.1111/apt.13737.
7. Tariq R, Weatherly R, Kammer P, etc. Experi- ence and outcomes at a specialized Clostridium difficile clinical practice. Mayo Clin Proc Innov Qual Outcomes. 2017;1(1):49-56. doi: 10.1016/j. mayocpiqo.2017.05.002.
8. Guo M, Tao W, Flavell R, et al. Potential intestinal infection and faecal-oral transmis- sion of SARS-CoV-2. Nat Rev Gastroenterol & Hepatol. 2021; 8(4):269-283. doi: org/10.1038/ s41575-021-00416-6.
9. Burchill E, Lymberopoulos E, Menozzi E, et al. The unique impact of COVID-19 on human gut microbiome research. Front Med. 2021;8:652464. doi: 10.3389/fmed.2021.652464.
10. Lakkasani S, Chan K, Shaaban H. Clos- tridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis. 2020;26(9):2299-2230. doi: org/10.3201/ eid2609.202505.
11. Sandhu A, Tillotson G, Polistico J, et al. Clostridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis. 2020;26(9):2272-2274. doi: org/10.3201/eid2609.202126.
12. Fishbein S, Hink T, Reske K, et al. Ran- domized controlled trial of oral vancomycin treatment in Clostridioides difficile-colonized patients. mSphere. 2021;6(1):e00936-20. doi: org/10.1128mSphere00936-20.
David M. Lyerly, PhD, is a Co-Founder and serves as Chief Science Officer for TECHLAB, Blacksburg, VA, which manufactures a variety of in vitro diagnostic tests for enteric diseases.
Jodie Y. Lee, MS, MBA is Director of Marketing at TECHLAB. She has spent 16 years in the life science and diagnostic industries.
Is your facility overdiagnosing and overtreating C. diffi cile disease?
Stand-alone molecular diagnostic testing for C. diffi cile can result in overdiagnosis, overtreatment, and increased healthcare costs.1
The C. DIFF QUIK CHEK COMPLETE®
test rules out C. diffi cile
with sensitivity equal to PCR, detects active toxin production, and complies with C. diffi cile infection guidelines.2,3,4
Polage, C.R. et al. JAMA: Internal Medicine. 2015; 175(11):1792-1801. Dubberke, E. et al. Journal of Clinical Microbiology. 2011. 49(8): 2887-93.
Kelly, C.R. et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of $MPTUSJEJPJEFT EJGGJ DJMF Infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124-1147. Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). McDonald et al. Clinical Infectious Diseases. 2018; cix1085.
For questions about ordering, contact us
1-800-TECHLAB x3048 |
cs@techlab.com
www.techlab.com
© 2021 TECHLAB, Inc. All rights reserved. All trademarks referenced are trademarks of TECHLAB, Inc. PN 11292021001
PROVEN DIAGNOSTIC PERFORMANCE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50
